Please sign in to follow a disease.
Dermatofibrosarcoma protuberans
MONDO:0011934Dermatofibrosarcoma protuberans (DFSP) is a rare infiltrating soft tissue sarcoma, generally of low grade malignancy, arising from the dermis of the skin and characteristically associated with a specific chromosomal translocation t(17;22).
Also known as: DFSP, dermatofibrosarcoma, dermatofibrosarcoma protuberans, familial dermatofibrosarcoma protuberans (subtype), giant cell fibroblastoma, metastatic dermatofibrosarcoma protuberans (subtype)
2829 clinical trials for this condition and its sub-types, 11 tagged with Dermatofibrosarcoma protuberans itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Dermatofibrosarcoma protuberans
-
Experimental drug combo aims to shrink Hard-to-Treat sarcomas
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs—peposertib and a low-dose form of the chemotherapy doxorubicin—in people with advanced sarcomas that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the combo can shrink tumors or s…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo aims to outsmart Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…
Phase 1 • Sponsor: Epkin • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo targets sarcoma in limbs
Disease control Recruiting nowThis study tests whether combining the immunotherapy drug pembrolizumab with chemotherapy drugs (melphalan and dactinomycin) delivered directly to the affected limb via isolated limb infusion can safely delay cancer growth. It enrolls 30 patients aged 12 and older with advanced s…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Proton beam boost: new hope for inoperable sarcomas?
Disease control Recruiting nowThis study tests whether a higher dose of proton radiation can better control inoperable soft tissue sarcomas without increasing side effects. Forty adults with these rare tumors will receive targeted radiation over 4 weeks. Researchers will also look at blood and imaging markers…
Phase 2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New 3-Week radiation plan aims to cut side effects for sarcoma patients
Disease control Recruiting nowThis study tests whether a personalized 3-week course of proton radiation before surgery for soft tissue sarcoma can reduce long-term side effects compared to standard X-ray radiation. About 110 adults in Norway will receive either proton or X-ray therapy, chosen individually for…
Phase 2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC